Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170219 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study
A Phase 2 study, sponsored by Adrian Hernandez.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03170219 is a Phase 2 study that was terminated before completion, run by Adrian Hernandez. The registered enrollment target is 11 participants.
The verdict
NCT03170219, a Phase 2 study, was terminated before completion, sponsored by Adrian Hernandez.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to usual care.
Interventions
- COMBINATION_PRODUCT subcutaneous furosemide and sc2wear device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2018-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170219
The ClinicalTrials.gov registry entry for NCT03170219 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Hernandez, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which subcutaneous furosemide and sc2wear device is the first listed.
NCT03170219 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170219 about?
NCT03170219 is a clinical study titled "Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study". To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to usual care.
What is the current status of trial NCT03170219?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2018-04-27. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT03170219?
The interventions under investigation include: subcutaneous furosemide and sc2wear device (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03170219?
This trial is sponsored by Adrian Hernandez, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.